NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernsteinโs 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET.
The webcast will be accessible from Royalty Pharmaโs โEventsโ page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industryโs leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharmaโs current portfolio includes royalties on more than 35 commercial products, including Vertexโs Trikafta, Johnson & Johnsonโs Tremfya, GSKโs Trelegy, Rocheโs Evrysdi, Servierโs Voranigo, Biogenโs Tysabri and Spinraza, AbbVie and Johnson & Johnsonโs Imbruvica, Astellas and Pfizerโs Xtandi, Pfizerโs Nurtec ODT, and Gileadโs Trodelvy, and 17 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
